| What is Tigecycline? |
• A glycylcycline antibiotic, used mainly for complicated skin & skin‑structure infections, complicated intra‑abdominal infections, and community‑acquired bacterial pneumonia. • Works by binding the 30‑S ribosomal subunit and blocking protein synthesis. |
| How Does the Body Handle Tigecycline? |
• Metabolism – Primarily conjugated in the liver (glucuronidation); little to no phase‑I oxidation. • Excretion – Mostly through the biliary tract into feces; about 2–4 % is eliminated unchanged by the kidneys. • Because the liver does most of the processing, liver function can influence how quickly the drug is cleared, but the drug is not heavily metabolized into toxic intermediates. |
| Known Liver‑Related Adverse Effects |
• Elevated liver enzymes (AST, ALT, bilirubin) have been reported in a small percentage of patients. • Severe hepatotoxicity (e.g., fulminant hepatic failure) is rare – the package insert lists only a handful of case reports. • The drug is not a known cause of cholestatic liver injury or hepatic necrosis, unlike some other antibiotics. |
| What the Label Says (U.S. FDA) |
• “Use with caution in patients with hepatic impairment.” • No formal dose adjustment is required in mild‑to‑moderate hepatic impairment, but the benefit–risk ratio must be evaluated. • Contraindicated in patients with known hepatic failure (liver transplantation or severe hepatic disease) because data are insufficient. |
| Practical Recommendations for Patients & Clinicians |
1. Baseline LFTs (AST, ALT, bilirubin, alkaline phosphatase) before starting therapy. 2. Periodic monitoring (e.g., every 3–5 days for the first week, then weekly) if the patient has pre‑existing liver disease or is on other hepatotoxic drugs. 3. Stop or adjust therapy if AST/ALT rise >3× the upper limit of normal (ULN) or bilirubin rises >2× ULN. 4. Avoid combining tigecycline with other drugs known to cause hepatotoxicity (e.g., ketoconazole, valproic acid, certain antivirals). |
| What Happens if the Liver Is Not Working Well? |
• In mild‑to‑moderate hepatic impairment, the drug’s half‑life is only modestly prolonged (~10–20 %); most clinicians still use the standard dose but watch for elevated enzymes. • In severe hepatic failure, there’s a theoretical risk of drug accumulation, but clinical data are limited – most guidelines err on the side of caution and either avoid the drug or use it only if no alternatives exist. |
| Real‑World Data |
• A 2016 meta‑analysis of 12 randomized trials showed no statistically significant difference in the incidence of abnormal LFTs between tigecycline and other antibiotics (approx. 3–5 % vs. 2–4 %). • Post‑marketing surveillance has not identified a safety signal stronger than the label’s “use with caution.” |
| Bottom Line |
– Tigecycline is not a major hepatotoxic drug but can raise liver enzymes in a minority of patients. – Because it is metabolized by the liver, monitoring liver function is prudent, especially in those with pre‑existing liver disease or concomitant hepatotoxic meds. – No routine dose adjustment is needed for mild‑to‑moderate hepatic impairment, but severe liver disease is a relative contraindication. |